Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women
Graphical abstract
Introduction
Poor sleep quality has been implicated in worse health outcomes in various clinical populations and also contributes to diminished physical and psychological well-being in otherwise healthy individuals (Lorton et al., 2006, Okun et al., 2013). In a variety of clinical populations, disrupted sleep has been linked to greater fatigue and poorer health (Lorton et al., 2006). Poor sleep quality can be ascertained objectively by overnight polysomnography and subjectively by questionnaires such as the Pittsburgh Sleep Quality Index (PSQI), which measures sleep quality overall and many of its components (Buysse et al., 1989).
Sleep is commonly disrupted during the course of chronic illnesses (Polo-Kantola et al., 2014) and can also be an important etiological, precipitating, or maintaining factor of disease (Lorton et al., 2006). Sleep deprivation and loss results in an activation of the immune system, which is evident on a cellular and genomic level (Irwin et al., 2006). In the context of inflammatory disorders such as ankylosing spondylitis, sleep quality overall and its composite parts (PSQI subscales) are positively correlated with symptom severity and with circulating C-Reactive Protein (CRP) levels (Aydin et al., 2015).
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a chronic unremitting condition with an estimated worldwide prevalence of 0.8–3.5% (Bhui et al., 2011), and is overrepresented among women (Klimas and Koneru, 2007). The disorder is a poorly misunderstood and debilitating inflammatory illness with no known etiology or cure. CFS/ME symptoms include post-exertional malaise, sore throat, and unrefreshing sleep, among other varied somatic symptoms. Research has revealed physiological manifestations of CFS/ME, such as dysregulated cortisol awakening response (CAR) and cytokine expression imbalance, which are associated with sleep disturbances in other contexts (Klimas and Koneru, 2007, Mariman et al., 2013, Wright et al., 2015). CFS/ME patients' sleep is typically reported as unrefreshing and/or frequently disturbed (Mariman et al., 2013). Recent research has identified subjective and objective accounts of poor sleep quality in CFS/ME—possibly identifying different sleep phenotypes (e.g. hypersomnia, insomnia-like phenotypes) (Gotts et al., 2013, Mariman et al., 2013). Other studies found that CFS/ME patients report poor sleep, even while demonstrating otherwise normal sleep by polysomnography, as compared to healthy age- and gender-matched controls (Maes et al., 2012a, Neu et al., 2007).
In addition to experiencing somatic symptoms and poor sleep, CFS/ME patients reveal increased pro-inflammatory cytokine levels when compared to healthy controls (Fletcher et al., 2009, Klimas and Koneru, 2007, Maes et al., 2012a, Maes et al., 2012b). Elevations in pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), and relatively lower levels of anti-inflammatory cytokines (including IL-13) were shown most consistently in CFS/ME patients vs. healthy controls (Fletcher et al., 2009, Gupta et al., 1997, Moss et al., 1999). However, no individual cytokine, set of cytokine expression profiles, or biomarker has been consistently and conclusively found to be a diagnostic marker or known etiological factor in CFS/ME (Broderick et al., 2010). Discrepancies in the CFS/ME cytokine research may be due in part to cytokine measurement issues, including the use of different assays, which change in sensitivity and specificity over time due to methodological and laboratory advances, or the time of day when samples are collected (Fletcher et al., 2009, Klimas et al., 2012, Nakamura et al., 2010, Pandi-Perumal et al., 2007). Inflammatory cytokine levels can also differ by gender, in part because of estrogen's immunomodulatory effects, including in the context of CFS/ME (Klimas and Koneru, 2007, Smylie et al., 2013). The sleep and inflammation literature is not always stratified by gender, which may account for some inconsistencies in the literature.
Poor sleep quality has been shown to contribute to greater inflammation in healthy, and in acutely and chronically ill individuals, though there is evidence for a bi-directional relationship (Irwin, 2002, Irwin et al., 2006, Lorton et al., 2006). In general, pro-inflammatory cytokines promote sleep while anti-inflammatory cytokines prevent sleep (Krueger, 2008, Krueger et al., 2007). IL-1 and TNF-α are consistently found to be directly somnogenic when administered centrally or peripherally (Krueger and Majde, 2003). In rats, IL-6 modulates NREM sleep and is known to contribute to sleepiness, but does not meet full criteria for a sleep regulating substance (Hogan et al., 2003).
Inflammatory control can be disturbed in individuals who suffer from primary sleep disorders, such as insomnia (Vgontzas et al., 2002, Weil et al., 2009). Chronic insomnia can result in a shift and disruption in the circadian release of IL-6 and TNF-α (Vgontzas et al., 2002). Inflammatory cytokines IL-6 and TNF-α are typically elevated in sleep disorders that result in excessive daytime sleepiness, such as sleep apnea and narcolepsy (Vgontzas et al., 1999, Vgontzas et al., 2002). In healthy adults, these cytokines are usually elevated after sleep deprivation and may mediate sleep propensity and fatigue the next day (Vgontzas et al., 1999). It is reasonable that sleep disruptions in CFS/ME patients may therefore promote increased pro-inflammatory signaling and symptomology, yet little is known about the precise relationship between aspects of sleep disruption and specific inflammatory and symptomalogic indicators in this population.
Given the association between sleep disruptions and illness severity and also with inflammation, we hypothesized that among women with CFS/ME poor sleep quality (higher PSQI global scores) would be associated with greater circulating pro-inflammatory cytokine levels, and more severe and frequent CFS/ME-related symptoms. Specifically, we hypothesized that poor sleep quality overall and certain subscales (i.e. sleep disturbances, sleep duration, and sleep latency) would predict (a) greater levels of circulating pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α, and (b) greater CFS/ME symptom burden including Centers for Disease Control and Prevention (CDC) core CFS/ME symptom severity and frequency, and greater fatigue severity and fatigue-related interference in daily life.
Section snippets
Participants and procedures
Female participants in this study were recruited from a larger study of stress and coping processes in CFS/ME patients and study findings have been previously published (Hall et al., 2014, Lattie et al., 2012). This is the first report on sleep-related phenomena from this study. All participants received a physician-determined CFS diagnosis, as defined by the CDC criteria (Fukuda et al., 1994). Recruitment methods included physician referral, support groups, CFS/ME conferences, and
Sample characteristics
As shown in Table 1, the mean age of the sample is 50.5 years, and 78.3% were non-Hispanic White. This was a highly educated sample, with 63% of the sample having attended at least some college, which is not atypical for this patient population (Jason et al., 2007, Servaes et al., 2001). Descriptive information on sleep quality, fatigue severity and interference, and CFS/ME symptom severity and frequency is provided in Table 1. Mean levels for cytokines were 31.91 pg/mL, 8.79 pg/mL, and 18.51 pg/mL
Discussion
Here we report that poor sleep quality is independently associated with more severe and interfering fatigue, greater severity and frequency of CFS/ME symptoms, and greater inflammatory cytokine levels in women suffering from CFS/ME. Concordant with previous research, we found that perceived poor sleep quality is highly prevalent in women suffering from CFS/ME. In this sample, nearly all cases were clinically defined “poor sleepers,” as defined by global PSQI score > 5. Characterization of sleep
Conclusion
Our preliminary findings of significant associations between self-reported sleep quality components and inflammatory indicators on the one hand and CFS/ME symptomology on the other justify further research in sleep medicine for CFS/ME patients, specifically addressing the mechanism behind these associations. The interpretations of our results are limited by a cross-sectional design; and the lack of a matched healthy control comparison group, nocturnal cytokine measurements, overnight
Conflict of interest
The authors report no conflicts of interest.
Sources of funding
This research was supported by the National Institutes of Health [grant number 1R01 NS055672]. DH was supported by an institutional National Research Service Award (T32AT000051) from the National Center for Complementary and Integrative Health at the National Institutes of Health.
References (72)
- et al.
Sleep quality in patients with ankylosing spondylitis
Rev. Bras. Reumatol.
(2015) - et al.
Monozygotic twins discordant for chronic fatigue syndrome: objective measures of sleep
J. Psychosom. Res.
(2004) - et al.
Formal analysis of cytokine networks in chronic fatigue syndrome
Brain Behav. Immun.
(2010) - et al.
The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research
Psychiatry Res.
(1989) - et al.
Sleep disturbance, cytokines, and fatigue in women with ovarian cancer
Brain Behav. Immun.
(2012) - et al.
Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome
J. Psychiatr. Res.
(1997) - et al.
Stress management skills, cortisol awakening response, and post-exertional malaise in chronic fatigue syndrome
Psychoneuroendocrinology
(2014) - et al.
Interleukin-6 alters sleep of rats
J. Neuroimmunol.
(2003) Effects of sleep and sleep loss on immunity and cytokines
Brain Behav. Immun.
(2002)- et al.
Sleep and chronic stress: new directions for allostatic load research
Sleep Med.
(2015)
Cytokines and pathological sleep
Sleep Med.
Biomarkers for chronic fatigue
Brain Behav. Immun.
Sleep and cytokines
Sleep Med. Clin.
Stress management skills, neuroimmune processes and fatigue levels in persons with chronic fatigue syndrome
Brain Behav. Immun.
Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin
J. Affect. Disord.
Validation of the three-factor model of the PSQI in a large sample of chronic fatigue syndrome (CFS) patients
J. Psychosom. Res.
Sleep in the chronic fatigue syndrome
Sleep Med. Rev.
Brain-immune interactions in sleep
Int. Rev. Neurobiol.
To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers
Brain Behav. Immun.
A population-based survey of sleep disturbances in middle-aged women—associations with health, health related quality of life and health behavior
Maturitas
Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis
Psychoneuroendocrinology
Simultaneous measurement of multiple ear proteins with multiplex ELISA assays
Hear. Res.
Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime
Metab. Clin. Exp.
Age-related sleep change: gender and estrogen effects on the subjective–objective sleep quality relationships of healthy, noncomplaining older men and women
J. Psychosom. Res.
Sleep deprivation attenuates inflammatory responses and ischemic cell death
Exp. Neurol.
Sleep characteristics, exercise capacity and physical activity in patients with chronic fatigue syndrome
Disabil. Rehabil.
Characterization of relationships between sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn's disease
J. Pediatr. Gastroenterol. Nutr.
Chronic fatigue syndrome in an ethnically diverse population: the influence of psychosocial adversity and physical inactivity
BMC Med.
Detection and quantification of cytokines and other biomarkers
Methods Mol. Biol.
From inflammation to sickness and depression: when the immune system subjugates the brain
Nat. Rev. Neurosci.
User's Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders: SCID-II
Plasma cytokines in women with chronic fatigue syndrome
J. Transl. Med.
Sleep quality and psychological adjustment in chronic fatigue syndrome
J. Behav. Med.
The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group
Ann. Intern. Med.
Are there sleep-specific phenotypes in patients with chronic fatigue syndrome? A cross-sectional polysomnography analysis
BMJ Open
Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory
Qual. Life Res.
Cited by (59)
Correlation between hemoglobin levels and depression in late-stage cancer patients with irritability as mediating variable
2023, European Journal of Oncology NursingSerum from Myalgic encephalomyelitis/chronic fatigue syndrome patients causes loss of coherence in cellular circadian rhythms
2023, Journal of NeuroimmunologyA randomized, placebo-controlled, double-blinded mechanistic clinical trial using endotoxin to evaluate the relationship between insomnia, inflammation, and affective disturbance on pain in older adults: A protocol for the sleep and Healthy Aging Research for pain (SHARE-P) study
2023, Brain, Behavior, and Immunity - HealthObjective sleep measures in chronic fatigue syndrome patients: A systematic review and meta-analysis
2023, Sleep Medicine ReviewsAnalysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome
2022, Journal of Advanced ResearchCircadian rhythm disruption in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for the post-acute sequelae of COVID-19
2022, Brain, Behavior, and Immunity - Health